Skip to main content

ProductLife Group Acquires IntiQuan, Strengthening Global Drug Development Capabilities

Written by Customer Service on . Posted in Mergers And Acquisitions.

PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — ProductLife Group (PLG), a global leader in regulatory, scientific, compliance, and digital transformation consulting services for the life sciences industry, is pleased to announce the acquisition of IntiQuan AG, a premier Swiss boutique specializing in pharmacometric services for the biopharmaceutical sector.

Founded in Switzerland in 2015 by Dr. Henning Schmidt, IntiQuan has rapidly established itself as a trusted provider of cutting-edge pharmacometric and statistical modelling & simulation services. The acquisition expands PLG’s portfolio of specialized solutions that support biopharmaceutical companies with drug development, adding a key set of capabilities focused on significantly reducing development risk, costs and timelines and enhancing patient safety through advanced dose-response analyses and predictive safety profiling.

With the addition of IntiQuan, PLG is now in a position to offer customers cutting-edge pharmacometrics services that include strategic consulting, pharmacokinetics/pharmacodynamics (PK/PD), population pharmacokinetics (popPK), and biosimulation services. IntiQuan is renowned for its track record of translating complex data into actionable insights across a range of therapeutic areas and modalities from pre-clinical to Phase IV. Its team of scientific experts leverages advanced mathematical modeling and simulation techniques to inform clinical study design as well as analyze and predict trial outcomes.

This acquisition represents the next step in PLG’s strategy to create a fully integrated global platform. With further expansions planned across the US and European markets, PLG is well on its way to becoming a leading global provider of comprehensive drug development services.

Xavier Duburcq, CEO of PLG, commented: “We are excited to welcome the IntiQuan team to PLG. They are a very strong fit with our expertise-driven organization. Their deep and highly specialized scientific knowledge in pharmacometrics and clinical pharmacology means that we will enhance the support we provide to our clients in their drug development journey. Pharmacometrics and model-informed drug development offer regulatory grade insights that can impact key decision-making and accelerate clinical development, even eliminating the need for certain trials, in some cases.”

Dr. Henning Schmidt, Founder of IntiQuan, added: “Joining forces with PLG is a pivotal moment for IntiQuan. Our teams support IntiQuan’s clients bringing breakthrough medicines to patients and reducing both time to market and the cost of research and development through our combined solutions. We are excited to contribute our unique capabilities to PLG’s global platform and to play a key role in advancing the future of drug development.”

Dr. Stefan Wetzel, CEO of IntiQuan, said: “There is strong cultural alignment between our organizations centered on providing high-quality, innovative and customer-focused solutions. Together with our PLG colleagues, we look forward to supporting our customers with a broader set of complementary solutions, for example in regulatory services.”

Advisors
Capitalmind Investec acted as M&A advisor, and Advestra acted as legal and tax advisor to the sellers.

DDA & Company and Hoffman & Partner acted as M&A advisors, RSM acted as financial and tax advisor, and CMS Von Erlach Partners acted as legal counsel to ProductLife Group.

About ProductLife Group:

ProductLife Group’s mission is to support patient access to safe and effective healthcare solutions by delivering worldwide consulting and outsourcing services through the entire product life.

Combining local expertise with global reach spanning more than 150 countries, PLG is the Life Sciences Industry reference strategic partner for the development, market introduction and life cycle management of product portfolios, and the related business and digital transformation.

With a goal of continuously improving the value delivered to teams and clients, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.

For more information, visit https://productlifegroup.com/
Contact:
Fabrice Galzin
ProductLife Group Head of Marketing
fgalzin@productlife-group.com

About IntiQuan
IntiQuan AG is a leading Swiss boutique specializing in Pharmacometrics, Statistical Modeling & Simulation, and Quantitative Systems Pharmacology (QSP) for the pharmaceutical and biopharmaceutical industries. IntiQuan offers high-end, fit-for-purpose solutions that are crucial for optimizing drug development and regulatory processes. Strategically located in Switzerland, IntiQuan is recognized for its expertise in integrating complex data for informed decision-making, making it a key player in advancing precision medicine and enhancing patient safety across a variety of therapeutic areas.

For more information, visit https://www.intiquan.com
Contact:
Stefan Wetzel
Chief Executive Officer
stefan.wetzel@intiquan.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.